Description
CinnaTropin is a brand name of recombinant human growth hormone (somatropin), produced to be structurally identical to endogenous growth hormone secreted by the human pituitary gland. The product is supplied as a ready-to-use solution in a sterile pre-filled injection pen, containing 10 mg of somatropin, equivalent to approximately 30 IU. CinnaTropin is developed for medical use and is referenced in clinical endocrinology for the management of growth hormone deficiency and specific growth-related conditions.
Somatropin plays a key role in normal growth, metabolism, and tissue maintenance. It is involved in protein synthesis, lipid metabolism, bone development, and regulation of body composition. In pediatric and adult medicine, recombinant growth hormone is used to support physiological growth processes in individuals with confirmed growth hormone deficiency or certain genetic and medical conditions affecting stature and development.
CinnaTropin is indicated for the treatment of pediatric patients with growth failure due to inadequate secretion of endogenous growth hormone. It is also indicated for children with short stature associated with Turner syndrome, Noonan syndrome, Prader-Willi syndrome, chronic renal insufficiency, idiopathic short stature (ISS), and for children born small for gestational age (SGA) who have not achieved catch-up growth by four years of age or later. In adults, CinnaTropin may be prescribed for individuals with childhood-onset or adult-onset growth hormone deficiency, as diagnosed by appropriate medical testing.
CinnaTropin should not be used in individuals with active malignancies, critical illness related to major surgery, trauma, or respiratory failure, or in patients with known hypersensitivity to somatropin or any of its components. It is contraindicated in children with closed epiphyseal growth plates and in specific high-risk cases of Prader-Willi syndrome, particularly when severe obesity or respiratory complications are present. Patients with diabetic retinopathy or uncontrolled diabetes require special medical evaluation before therapy.
During treatment, careful medical supervision is required. Somatropin can influence glucose metabolism, and patients with diabetes may require adjustments to insulin or other hypoglycemic medications. Symptoms such as persistent headache, visual changes, nausea, vomiting, joint pain, or limping should be promptly reported to a healthcare provider, as they may indicate increased intracranial pressure or musculoskeletal complications.
Potential side effects reported in clinical use include fluid retention (edema), headache, paresthesia, injection-site reactions, joint pain, hypothyroidism, gastrointestinal discomfort, and upper respiratory tract infections. Not all patients experience adverse effects, and the frequency and intensity may vary depending on individual sensitivity and underlying health conditions.
CinnaTropin is administered via subcutaneous injection using the pre-filled pen system. Dosage and treatment duration must always be determined by a qualified healthcare professional based on individual medical evaluation. This product is not intended for self-medication or non-medical use.
For storage, unopened CinnaTropin pens should be kept refrigerated at temperatures between 2°C and 8°C and protected from light. The product must not be frozen. After first use, remaining solution may be stored in a refrigerator and used within four weeks, or stored at room temperature not exceeding 25°C and used within three weeks. Any solution that appears cloudy, contains particles, or shows signs of leakage should not be used. The product should always be kept out of reach of children.
This content is provided strictly for informational and educational purposes and does not replace professional medical advice. CinnaTropin is a prescription medication that affects endocrine function and should only be used within appropriate legal and clinical frameworks under medical supervision.